Phase III
Genentech is planning to seek regulatory approval for a blended lung cancer treatment following positive interim results from a late-stage trial that showed a combination of Tecentriq and Avastin plus chemotherapy enabled patients to live longer.
Novartis released full results from its Phase III EXPAND trial of siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS), which it published in the journal The Lancet.
Array BioPharma Inc. released detailed results for its late-stage combination treatment for metastatic melanoma.
AstraZeneca’s drug Farxiga could receive a new indication for a subset of diabetes patients based on Phase III data that was released today.
Tecentriq’s Phase III results gives Genentech a lead for potentially becoming the first-line treatment for squamous non-small cell lung cancer.
Heron Therapeutics said its late-stage anesthetic used to treat bunionectomy and hernia repair hit all primary and key secondary endpoints in two Phase III trials that cut down on the requirement of opioid drugs to treat pain – a significant point as the nation is in the grip of an opioid epidemic.
Alzheon hopes to raise about $80 million, which will help fund two Phase III clinical trials for its ALZ-801 for Alzheimer’s disease.
Regeneron Pharmaceuticals announced positive topline data from its Phase III PANORAMA clinical trial of Eylea (aflibercept) injection in moderately severe to severe non-proliferative diabetic retinopathy.
Alexion Pharmaceuticals announced positive results from its pivotal Phase III clinical trial for a life-threatening blood disease.
Here’s a look at eight biopharma companies with upcoming catalysts.
PRESS RELEASES